Joel D A Tyndall

List of Publications by Year
in descending order

107	6,237	76196	69108
papers	citations	40 h-index	77 g-index

113	113	113	8444
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Design, synthesis and biological evaluation of P2-modified proline analogues targeting the HtrA serine protease in Chlamydia. European Journal of Medicinal Chemistry, 2022, 230, 114064.	2.6	2
2	Characterisation of Candida parapsilosis CYP51 as a Drug Target Using Saccharomyces cerevisiae as Host. Journal of Fungi (Basel, Switzerland), 2022, 8, 69.	1.5	11
3	Structure-activity relationships of N-terminal variants of peptidomimetic tissue transglutaminase inhibitors. European Journal of Medicinal Chemistry, 2022, 232, 114172.	2.6	12
4	Improving Antibacterial Activity of a HtrA Protease Inhibitor JO146 against Helicobacter pylori: A Novel Approach Using Microfluidics-Engineered PLGA Nanoparticles. Pharmaceutics, 2022, 14, 348.	2.0	3
5	An amiloride derivative is active against the F1Fo-ATP synthase and cytochrome bd oxidase of Mycobacterium tuberculosis. Communications Biology, 2022, 5, 166.	2.0	21
6	S-217622, a 3CL Protease Inhibitor and Clinical Candidate for SARS-CoV-2. Journal of Medicinal Chemistry, 2022, 65, 6496-6498.	2.9	27
7	Development of Chromenopyrazole-Based Selective Cannabinoid 2 Receptor Agonists. Australian Journal of Chemistry, 2021, 74, 433.	0.5	1
8	Targeting Macrophage Migration Inhibitory Factor in Acute Pancreatitis and Pancreatic Cancer. Frontiers in Pharmacology, 2021, 12, 638950.	1.6	16
9	A single point mutation converts a glutaryl-7-aminocephalosporanic acid acylase into an N-acyl-homoserine lactone acylase. Biotechnology Letters, 2021, 43, 1467-1473.	1.1	0
10	A multi-strategy platform for quality control and Q-markers screen of Chaiqin chengqi decoction. Phytomedicine, 2021, 85, 153525.	2.3	19
11	Development and use of Clickable and Irreversible Probes for Detection of G Proteinâ€Coupled Receptors. FASEB Journal, 2021, 35, .	0.2	0
12	Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment. Recent Patents on Anti-Cancer Drug Discovery, 2021, 16, 479-497.	0.8	7
13	Development of Covalent, Clickable Probes for Adenosine A₁ and A₃ Receptors. Journal of Medicinal Chemistry, 2021, 64, 8161-8178.	2.9	7
14	Optimization of peptide-based inhibitors targeting the HtrA serine protease in Chlamydia: Design, synthesis and biological evaluation of pyridone-based and N-Capping group-modified analogues. European Journal of Medicinal Chemistry, 2021, 224, 113692.	2.6	12
15	Cytostatic Action of Novel Histone Deacetylase Inhibitors in Androgen Receptor-Null Prostate Cancer Cells. Pharmaceuticals, 2021, 14, 103.	1.7	10
16	Chemical Synthesis of the PAX Protein Inhibitor EG1 and Its Ability to Slow the Growth of Human Colorectal Carcinoma Cells. Frontiers in Oncology, 2021, 11, 709540.	1.3	0
17	Structural Insights into the Azole Resistance of the Candida albicans Darlington Strain Using Saccharomyces cerevisiae Lanosterol 14Î±-Demethylase as a Surrogate. Journal of Fungi (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.4	4
18	Type I interferons are important coâ€stimulatory signals during T cell receptor mediated human MAIT cell activation. European Journal of Immunology, 2020, 50, 178-191.	1.6	38

#	Article	IF	Citations
19	Engineered biosynthesis of cyclotides. New Zealand Journal of Botany, 2020, 58, 358-377.	0.8	2
20	Neutrophils suppress mucosalâ€associated invariant TÂcells in humans. European Journal of Immunology, 2020, 50, 643-655.	1.6	8
21	Structure-activity analysis of peptidic Chlamydia HtrA inhibitors. Bioorganic and Medicinal Chemistry, 2019, 27, 4185-4199.	1.4	6
22	TCR- or Cytokine-Activated CD8+ Mucosal-Associated Invariant T Cells Are Rapid Polyfunctional Effectors That Can Coordinate Immune Responses. Cell Reports, 2019, 28, 3061-3076.e5.	2.9	138
23	Azole Resistance Reduces Susceptibility to the Tetrazole Antifungal VT-1161. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	29
24	Impact of Homologous Resistance Mutations from Pathogenic Yeast on Saccharomyces cerevisiae Lanosterol 14Î±-Demethylase. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	19
25	Synthesis of novel (benzimidazolyl)isoquinolinols and evaluation as adenosine A1 receptor tools. RSC Advances, 2018, 8, 16362-16369.	1.7	3
26	Stereochemical basis for the anti-chlamydial activity of the phosphonate protease inhibitor JO146. Tetrahedron, 2018, 74, 1184-1190.	1.0	5
27	Alkyl indole-based cannabinoid type 2 receptor tools: Exploration of linker and fluorophore attachment. European Journal of Medicinal Chemistry, 2018, 145, 770-789.	2.6	15
28	Proteases and protease inhibitors in infectious diseases. Medicinal Research Reviews, 2018, 38, 1295-1331.	5.0	130
29	Development of selective, fluorescent cannabinoid type 2 receptor ligands based on a 1,8-naphthyridin-2-(1H)-one-3-carboxamide scaffold. MedChemComm, 2018, 9, 2055-2067.	3.5	14
30	Crystal Structures of Full-Length Lanosterol 14Î±-Demethylases of Prominent Fungal Pathogens Candida albicans and Candida glabrata Provide Tools for Antifungal Discovery. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	54
31	Heterologous Expression of Full-Length Lanosterol 14Î±-Demethylases of Prominent Fungal Pathogens Candida albicans and Candida glabrata Provides Tools for Antifungal Discovery. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	11
32	Stability, Kinetic, and Mechanistic Investigation of 1,8-Self-Immolative Cinnamyl Ether Spacers for Controlled Release of Phenols and Generation of Resonance and Inductively Stabilized Methides. Organic Letters, 2017, 19, 528-531.	2.4	6
33	CtHtrA: the lynchpin of the chlamydial surface and a promising therapeutic target. Future Microbiology, 2017, 12, 817-829.	1.0	7
34	Intrinsic short-tailed azole resistance in mucormycetes is due to an evolutionary conserved aminoacid substitution of the lanosterol 14Î±-demethylase. Scientific Reports, 2017, 7, 15898.	1.6	59
35	Chemical Tools for Studying Lipid-Binding Class A G Proteinâ€“Coupled Receptors. Pharmacological Reviews, 2017, 69, 316-353.	7.1	20
36	Structural and Functional Elucidation of Yeast Lanosterol 14Î±-Demethylase in Complex with Agrochemical Antifungals. PLoS ONE, 2016, 11, e0167485.	1.1	43

#	Article	IF	Citations
37	Chlamydia Serine Protease Inhibitor, targeting HtrA, as a New Treatment for Koala Chlamydia infection. Scientific Reports, 2016, 6, 31466.	1.6	27
38	Triazole resistance mediated by mutations of a conserved active site tyrosine in fungal lanosterol 14Î±-demethylase. Scientific Reports, 2016, 6, 26213.	1.6	80
39	A Chlamydia trachomatis strain with a chemically generated amino acid substitution (P370L) in the cthtrA gene shows reduced elementary body production. BMC Microbiology, 2015, 15, 194.	1.3	8
40	Pinnatoxins E, F and G target multiple nicotinic receptor subtypes. Journal of Neurochemistry, 2015, 135, 479-491.	2.1	15
41	Structural Insights into Binding of the Antifungal Drug Fluconazole to Saccharomyces cerevisiae Lanosterol 14Î±-Demethylase. Antimicrobial Agents and Chemotherapy, 2015, 59, 4982-4989.	1.4	134
42	Multiple binding modes of isothiocyanates that inhibit macrophage migration inhibitory factor. European Journal of Medicinal Chemistry, 2015, 93, 501-510.	2.6	23
43	Anxiogenic and Stressor Effects of the Hypothalamic Neuropeptide RFRP-3 Are Overcome by the NPFFR Antagonist GJ14. Endocrinology, 2015, 156, 4152-4162.	1.4	49
44	Assessing inhibition of macrophage migration inhibitory factor by isothiocyanates. Free Radical Biology and Medicine, 2015, 86, S42-S43.	1.3	0
45	Architecture of a single membrane spanning cytochrome P450 suggests constraints that orient the catalytic domain relative to a bilayer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3865-3870.	3.3	231
46	Potent inhibition of macrophage migration inhibitory factor (MIF) by myeloperoxidase-dependent oxidation of epicatechins. Biochemical Journal, 2014, 462, 303-314.	1.7	23
47	Identification of a serine protease inhibitor which causes inclusion vacuole reduction and is lethal to <scp>C</scp>hlamydia trachomatis. Molecular Microbiology, 2013, 89, 676-689.	1.2	55
48	Heterologous expression ofCandida albicansPma1p inSaccharomyces cerevisiae. FEMS Yeast Research, 2013, 13, 302-311.	1.1	7
49	Proteolytic activation of Chlamydia trachomatis HTRA is mediated by PDZ1 domain interactions with protease domain loops L3 and LC and beta strand Î²5. Cellular and Molecular Biology Letters, 2013, 18, 522-37.	2.7	10
50	Catalysis product captured in lumazine synthase from the fungal pathogenCandida glabrata. Acta Crystallographica Section D: Biological Crystallography, 2013, 69, 1580-1586.	2.5	4
51	Insight into Pleiotropic Drug Resistance ATP-binding Cassette Pump Drug Transport through Mutagenesis of Cdr1p Transmembrane Domains*. Journal of Biological Chemistry, 2013, 288, 24480-24493.	1.6	42
52	Variable Expression of GLIPR1 Correlates with Invasive Potential in Melanoma Cells. Frontiers in Oncology, 2013, 3, 225.	1.3	25
53	[Fe2L3]4+ Cylinders Derived from Bis(bidentate) 2-Pyridyl-1,2,3-triazole â€œClickâ€•Ligands: Synthesis, Structures and Exploration of Biological Activity. Molecules, 2013, 18, 6383-6407.	1.7	56
54	Crystallization of Erg11p â€“ the cytochrome P450 target of triazole antifungals. Acta Crystallographica Section A: Foundations and Advances, 2013, 69, s62-s62.	0.3	0

#	Article	IF	Citations
55	Macrophage migration inhibitory factor covalently complexed with phenethyl isothiocyanate. Acta Crystallographica Section F: Structural Biology Communications, 2012, 68, 999-1002.	0.7	11
56	The Active Site Residue V266 of Chlamydial HtrA Is Critical for Substrate Binding during both in vitro and in vivo Conditions. Journal of Molecular Microbiology and Biotechnology, 2012, 22, 10-16.	1.0	13
57	Specific interactions between the Candida albicans ABC transporter Cdr1p ectodomain and a <scp>d</scp>â€octapeptide derivative inhibitor. Molecular Microbiology, 2012, 85, 747-767.	1.2	41
58	Homology modeling and functional testing of an ABCA1 mutation causing Tangier disease. Atherosclerosis, 2011, 218, 404-410.	0.4	11
59	Unique Residues Involved in Activation of the Multitasking Protease/Chaperone HtrA from Chlamydia trachomatis. PLoS ONE, 2011, 6, e24547.	1.1	26
60	Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA). Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6760-6766.	1.0	32
61	Honey Bee Dopamine and Octopamine Receptors Linked to Intracellular Calcium Signaling Have a Close Phylogenetic and Pharmacological Relationship. PLoS ONE, 2011, 6, e26809.	1.1	72
62	Update 1 of: Over One Hundred Peptide-Activated G Protein-Coupled Receptors Recognize Ligands with Turn Structure. Chemical Reviews, 2010, 110, PR1-PR41.	23.0	66
63	Targeting the chromosome partitioning protein ParA in tuberculosis drug discovery. Journal of Antimicrobial Chemotherapy, 2010, 65, 2347-2358.	1.3	27
64	In vivo seizure induction and affinity studies of domoic acid and isodomoic acids-D, -E and -F. Neuropharmacology, 2010, 59, 129-138.	2.0	21
65	Update 1 of: Beta-Strand Mimetics. Chemical Reviews, 2010, 110, PR32-PR69.	23.0	85
66	Update 1 of: Proteases Universally Recognize Beta Strands In Their Active Sites. Chemical Reviews, 2010, 110, PR1-PR31.	23.0	144
67	Abc1p Is a Multidrug Efflux Transporter That Tips the Balance in Favor of Innate Azole Resistance in Candida krusei. Antimicrobial Agents and Chemotherapy, 2009, 53, 354-369.	1.4	93
68	Direct Modification of the Proinflammatory Cytokine Macrophage Migration Inhibitory Factor by Dietary Isothiocyanates. Journal of Biological Chemistry, 2009, 284, 32425-32433.	1.6	70
69	The orf virus inhibitor of apoptosis functions in a Bcl-2-like manner, binding and neutralizing a set of BH3-only proteins and active Bax. Apoptosis: an International Journal on Programmed Cell Death, 2009, 14, 1317-1330.	2.2	39
70	The Toxicogenomic Multiverse: Convergent Recruitment of Proteins Into Animal Venoms. Annual Review of Genomics and Human Genetics, 2009, 10, 483-511.	2.5	683
71	Crystal Structures of Highly Constrained Substrate and Hydrolysis Products Bound to HIV-1 Protease. Implications for the Catalytic Mechanism. Biochemistry, 2008, 47, 3736-3744.	1.2	21
72	Cannabinoid CB1 and CB2 Receptor Ligand Specificity and the Development of CB2-Selective Agonists. Current Medicinal Chemistry, 2008, 15, 1428-1443.	1.2	81

#	Article	IF	Citations
73	Peptides and Small Molecules Targeting the Plasminogen Activation System: Towards Prophylactic Anti-Metastasis Drugs for Breast Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2008, 3, 1-13.	0.8	24
74	Sequence requirements for splicing by the Cne PRP8 intein. FEBS Letters, 2007, 581, 3000-3004.	1.3	18
75	Enzyme Adaptation to Inhibitor Binding:â€‰ A Cryptic Binding Site in Phenylethanolamine N-Methyltransferase. Journal of Medicinal Chemistry, 2007, 50, 4845-4853.	2.9	26
76	Design, Synthesis, Potency, and Cytoselectivity of Anticancer Agents Derived by Parallel Synthesis from l±-Aminosuberic Acid. Journal of Medicinal Chemistry, 2006, 49, 7611-7622.	2.9	67
77	A theory of mode of action of azolylalkylquinolines as DNA binding agents using automated flexible ligand docking. Journal of Molecular Graphics and Modelling, 2006, 25, 459-469.	1.3	21
78	GPCR Agonists and Antagonists in the Clinic. Medicinal Chemistry, 2005, 1, 405-421.	0.7	84
79	Disulfide-linked dimers of human adrenaline synthesizing enzyme PNMT are catalytically active. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2005, 1750, 82-92.	1.1	4
80	Beta-Strand Mimetics. ChemInform, 2005, 36, no.	0.1	0
81	Over One Hundred Peptide-Activated G Protein-Coupled Receptors Recognize Ligands with Turn Structure. ChemInform, 2005, 36, no.	0.1	0
82	Proteases Universally Recognize ? Strands in Their Active Sites. ChemInform, 2005, 36, no.	0.1	1
83	Site-directed Mutagenesis and Kinetic Studies of the West Nile Virus NS3 Protease Identify Key Enzyme-Substrate Interactions. Journal of Biological Chemistry, 2005, 280, 2896-2903.	1.6	56
84	Comparative Agonist/Antagonist Responses in Mutant Human C5a Receptors Define the Ligand Binding Site. Journal of Biological Chemistry, 2005, 280, 17831-17840.	1.6	47
85	Proteases Universally Recognize Beta Strands In Their Active Sites. Chemical Reviews, 2005, 105, 973-1000.	23.0	371
86	Mode of Binding of Methyl Acceptor Substrates to the Adrenaline-Synthesizing Enzyme Phenylethanolamine N-Methyltransferase:â€‰ Implications for Catalysis. Biochemistry, 2005, 44, 16875-16885.	1.2	24
87	Structural, Mutagenic, and Kinetic Analysis of the Binding of Substrates and Inhibitors of Human Phenylethanolamine N-Methyltransferase. Journal of Medicinal Chemistry, 2005, 48, 7243-7252.	2.9	26
88	Over One Hundred Peptide-Activated G Protein-Coupled Receptors Recognize Ligands with Turn Structure. Chemical Reviews, 2005, 105, 793-826.	23.0	219
89	Potent Cyclic Antagonists of the Complement C5a Receptor on Human Polymorphonuclear Leukocytes. Relationships between Structures and Activity. Molecular Pharmacology, 2004, 65, 868-879.	1.0	100
90	Enzymatic Characterization and Homology Model of a Catalytically Active Recombinant West Nile Virus NS3 Protease. Journal of Biological Chemistry, 2004, 279, 48535-48542.	1.6	103

#	Article	IF	Citations
91	Determination ofÎ±-conotoxin binding modes on neuronal nicotinic acetylcholine receptors. Journal of Molecular Recognition, 2004, 17, 339-347.	1.1	40
92	Formation of mononuclear and chloro-bridged binuclear copper(II) complexes of patellamide D, a naturally occurring cyclic peptide: influence of anion and solvent. Journal of Inorganic Biochemistry, 2004, 98, 1857-1866.	1.5	28
93	Countering Cooperative Effects in Protease Inhibitors Using Constrained Î²-Strand-Mimicking Templates in Focused Combinatorial Libraries. Journal of Medicinal Chemistry, 2004, 47, 1641-1651.	2.9	47
94	Beta-Strand Mimetics. Chemical Reviews, 2004, 104, 6085-6118.	23.0	215
95	D-Tyrosine as a Chiral Precusor to Potent Inhibitors of Human Nonpancreatic Secretory Phospholipase A2 (IIa) with Antiinflammatory Activity. ChemBioChem, 2003, 4, 181-185.	1.3	72
96	Designing supramolecular structures from models of cyclic peptide scaffolds with heterocyclic constraints. Journal of Molecular Graphics and Modelling, 2003, 21, 341-355.	1.3	26
97	Conformationally Homogeneous Cyclic Tetrapeptides:â€‰ Useful New Three-Dimensional Scaffolds. Journal of the American Chemical Society, 2003, 125, 640-641.	6.6	67
98	Isolation and Characterization of a Cone Snail Protease with Homology to CRISP Proteins of the Pathogenesis-related Protein Superfamily. Journal of Biological Chemistry, 2003, 278, 31105-31110.	1.6	202
99	Î²-Strand Mimicking Macrocyclic Amino Acids:â€‰ Templates for Protease Inhibitors with Antiviral Activity. Journal of Medicinal Chemistry, 2002, 45, 371-381.	2.9	73
100	Crystal Structure of a Thermostable Lipase from Bacillus stearothermophilus P1. Journal of Molecular Biology, 2002, 323, 859-869.	2.0	121
101	Expression, purification, crystallization and preliminary crystallographic analysis of a thermostable lipase fromBacillus stearothermophilusP1. Acta Crystallographica Section D: Biological Crystallography, 2002, 58, 182-185.	2.5	13
102	Macrocycles Mimic The Extended Peptide Conformation Recognized By Aspartic, Serine, Cysteine and Metallo Proteases. Current Medicinal Chemistry, 2001, 8, 893-907.	1.2	90
103	Synthesis, Stability, Antiviral Activity, and Protease-Bound Structures of Substrate-Mimicking Constrained Macrocyclic Inhibitors of HIV-1 Protease. Journal of Medicinal Chemistry, 2000, 43, 3495-3504.	2.9	68
104	Conformational Selection of Inhibitors and Substrates by Proteolytic Enzymes:Â Implications for Drug Design and Polypeptide Processing. Journal of Medicinal Chemistry, 2000, 43, 1271-1281.	2.9	146
105	Conformational homogeneity in molecular recognition by proteolytic enzymes. Journal of Molecular Recognition, 1999, 12, 363-370.	1.1	61
106	Cu(II) Potentiation of Alzheimer AÎ² Neurotoxicity. Journal of Biological Chemistry, 1999, 274, 37111-37116.	1.6	688
107	Covalent cannabinoid receptor ligands â€“ structural insight and selectivity challenges. RSC Medicinal Chemistry, 0, , .	1.7	0